Department of Interaction Science, Sungkyunkwan University, Seoul 03063, Korea.
Int J Environ Res Public Health. 2021 Jan 25;18(3):1045. doi: 10.3390/ijerph18031045.
The purpose of this study was to analyze the performance of pharmaceutical companies' business diversification into medical devices in terms of their technical efficiency (TE) as compared to that of traditional pharmaceutical companies. For a total of 174 externally audited pharmaceutical companies engaged in the drug product business between 2008 and 2019, pharmaceutical companies were classified into two groups according to medical device business diversification. The TE of pharmaceutical companies that diversify the medical device business was lower than that of traditional pharmaceutical companies. However, in terms of the meta-technology ratio (MTR) calculated using meta-frontier analysis, pharmaceutical companies diversified into medical devices showed higher MTR than the traditional pharmaceutical company group. The results imply that the corporate performance growth potential of traditional pharmaceutical companies is lower than that of pharmaceutical companies that have diversified into the medical device business.
本研究旨在分析制药公司向医疗器械业务多元化的表现，比较其技术效率（TE）与传统制药公司的表现。在 2008 年至 2019 年期间，共有 174 家经外部审计从事药品业务的制药公司，根据医疗器械业务多元化将制药公司分为两组。开展医疗器械业务多元化的制药公司的 TE 低于传统制药公司。然而，使用超前沿分析计算的元技术比率（MTR）来看，多元化进入医疗器械领域的制药公司的 MTR 高于传统制药公司组。研究结果表明，传统制药公司的企业业绩增长潜力低于多元化进入医疗器械业务的制药公司。
